COPCOV trial

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting


What’s the COPCOV trial about?

Even with good infection control, people who work in healthcare settings are at higher risk of COVID-19 than other people.

The antiviral activity of hydroxychloroquine (HCQ) may protect people exposed to COVID-19 from catching it.

masked doctor

smiling doctor

Is taking HCQ like this safe?

Yes. HCQ has been used for decades to treat rheumatological disease and we know it’s safe in most people.*
*people with certain medical conditions or taking specific medicines will be identified at screening and advised not to participate in the COPCOV trial.

Should I worry about side effects?

We expect most people taking HCQ in the COPCOV study will get either no side-effects or minor symptoms.

Could HCQ really be used to prevent COVID-19?

HCQ is not patented, easy and cheap to make and has a long shelf-life without refrigeration. If COPCOV finds it does protect from COVID-19 it could be widely used across the world.


If COPCOV finds that HCQ can prevent COVID-19 infection it could be used alongside any future vaccines to combat the COVID-19 pandemic worldwide.

UK Recruitment Count:


Current UK recruitment sites: (Recruitment in the UK has now stopped)

  • Brighton and Sussex University Hospitals NHS Trust
  • Oxford University Hospitals NHS Trust
  • Imperial College Healthcare NHS Trust
  • University Hospitals Coventry and Warwickshire NHS Trust
  • University Hospitals of Morecambe Bay NHS Trust
  • Dudley Group NHS Trust
  • Birmingham & Solihull Mental Health NHS Trust
  • Rotherham, Doncaster And South Humber NHS Foundation Trust
  • The Princess Alexandra NHS Trust
  • Lewisham & Greenwich NHS Trust

For Participants

Read more about taking part in COPCOV here

View details »

For Trial Sites

Key study documents and information for sites running COPCOV in the UK

View details »


Find out more about the UK progress of the trial

View details »